Engineered bone matrix models for understanding breast cancer skeletal metastasis
Abstract
Bone is the most common site of metastasis in patients with advanced breast cancer and serves as a reservoir from which secondary metastases often originate. While research has traditionally focused on understanding the biochemical signals involved in bone metastasis, bone matrix changes are inextricably linked with its pathogenesis as well. Indeed, decreased bone matrix density is both a symptom of late-stage disease and a risk factor for metastasis formation. Vice versa, raising bone density protects against metastasis. How bone matrix controls metastatic outgrowth and progression and which biochemical or biophysical mechanisms are involved in these processes is poorly understood due in part to limitations in current models of bone metastasis. In this review, we discuss the role of bone matrix in the microenvironmental regulation of bone metastasis and its effect on mechanosignaling and highlight current and future engineered model systems that have the potential to yield new mechanistic insights to advance the clinical prognosis of breast cancer patients.
Read the paper
Related studies
- Irisin Enhances Osteoblast DifferentiationIn Vitro
- Glucocorticoids suppress Wnt16 expression in osteoblasts in vitro and in vivo
- Interaction between Schwann Cells and Osteoblasts In Vitro
- Administration of cinnamaldehyde promotes osteogenesis in ovariectomized rats and differentiation of osteoblast in vitro
- The Effect of the Major Components of Fructus Cnidii on Osteoblasts In Vitro
- Estrogen depletion alters osteogenic differentiation and matrix production by osteoblasts in vitro
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.